GlassScriptPhysician profile
John Henry Mani
NPI 1548374234
$3,070.27
in general payments reported to CMS, 2019-2025
28 companies · $76.91 in 2025
The $76.91 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $203 · 2021: $594 · 2022: $441 · 2023: $859 · 2024: $542 · 2025: $76.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $764.54 | 2019-2025 | Xtandi, Myrbetriq |
| Dornier Medtech America, INC | $319.33 | 2023 | Dornier Medtech |
| Endo Pharmaceuticals INC. | $251.17 | 2020-2024 | Xiaflex |
| Sumitomo Pharma America, INC. | $195.62 | 2023 | Gemtesa |
| Axonics, INC. | $176.22 | 2021-2023 | Axonics, Bulkamid |
| Pfizer INC. | $170.64 | 2019-2025 | |
| Endo USA, INC. | $126.58 | 2024-2025 | Xiaflex |
| Blue Earth Diagnostics | $115.50 | 2019-2022 | |
| Teleflex LLC | $108.77 | 2023-2024 | Urolift |
| Boston Scientific Corporation | $105.93 | 2019-2025 | Polaris Ultra |
| Abbvie INC. | $101.29 | 2019-2024 | |
| Intuitive Surgical, INC. | $91.23 | 2021-2023 | Da Vinci Surgical System |
| Procept Biorobotics Corporation | $89.65 | 2024 | Aquabeam System |
| Urovant Sciences INC | $82.67 | 2021-2022 | |
| Neotract INC. | $76.44 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $60.98 | 2019-2022 | |
| Myovant Sciences INC. | $30.13 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.86 | 2024 | Givlaari |
| 180 Medical, INC. | $25.77 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $23.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.75 | 2023 | |
| Ambu INC. | $21.28 | 2023 | |
| Laborie Medical Technologies Corp. | $19.75 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Vertex Pharmaceuticals Incorporated | $17.29 | 2024 | |
| Allergan, INC. | $17.18 | 2021 | |
| Merck Sharp & Dohme LLC | $15.71 | 2023 | Welireg, Keytruda, Lynparza |
| Sagent Pharmaceuticals | $11.07 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.